Raymond Sanchez

Dr Raymond Sanchez is a psychiatrist and biopharmaceutical executive with more than twenty years of academic, medical and pharmaceutical industry experience across CNS, psychiatry, and digital health.

Dr Sanchez was the Chief Medical Officer of Cerevel Therapeutics, focused on the global development of novel and innovative treatments in CNS/Neuro-Psychiatry, until August 2024 when Cerevel was acquired by AbbVie for $8.7 billion. He is now a Senior Advisor at Bain Capital Life Sciences as well as a Board member and Scientific Advisory member for several organizations.

Dr Sanchez has played a key role in the development and global approval of drugs such as Abilify, Abilify Maintena, Rexulti and Abilify MyCite, the first FDA approved small molecule/digital combination therapy to monitor ingestion. His leadership has shaped development portfolios from early phase to late-stage programswith specific innovative study designs with significant global business impact.

He is a member of the Neuroscience Forum of the Academies of Science, Engineering and Medicine, and is the recipient of the prestigious 'Top 100 Leaders in Healthcare' award by the International Forum on Advancements in Healthcare (IFAH) as well as one of the Pharma Leaders by Pharmaceutical Executive magazine.

Dr. Sanchez received an A.B. in Psychology with Distinction and Phi Beta Kappa from Northwestern University, and trained in psychiatry at the Yale School of Medicine, where he was Chief Resident and Instructor before joining the life sciences industry.